T Cell All

Overview

• Definition:
  T Cell All refers to T cell–mediated immune responses, including hypersensitivity reactions, whereby T lymphocytes recognize antigens or allergens and mediate immune effects such as inflammation, tissue damage, or tolerance breakdown. This includes Type IV delayed hypersensitivity reactions and T cell involvement in allergic diseases.

• Epidemiology:
  T cell-mediated hypersensitivity reactions constitute a significant subset of immune-mediated adverse drug reactions and allergic disorders. For example, T cell–mediated delayed hypersensitivity accounts for less than 20% of all adverse drug reactions. Food allergy, partly driven by T cell dysregulation, affects nearly 8% of children. Allergic diseases involving T cells, such as atopic dermatitis and asthma, show increasing prevalence in industrialized countries.

• Classification:

• Type IV hypersensitivity reactions (delayed type): mediated by different T cell subsets (CD4+, CD8+).
• Regulatory T cells (Tregs): CD4+, CD25+, Foxp3+ cells critical for immune tolerance.
• Effector T cell subsets involved in allergies: Th2, Th9, Th17, Th22, Follicular helper T cells (Tfh).
• T regulatory type 1 (Tr1) cells: induced, FOXP3-negative peripheral Tregs involved in tolerance.

Pathophysiology

• Mechanism:
• T cells recognize antigens via T cell receptors (TCR), leading to activation and cytokine production.
• Type IV hypersensitivity involves antigen-specific T cells that cause tissue injury via cytokines and recruitment of inflammatory cells (macrophages, eosinophils).
• Allergic reactions often involve a Th2-skewed response, promoting IgE production by B cells and activation of mast cells/basophils.
• Regulatory T cells maintain tolerance by suppressing effector T cell function and blocking IgE production through cytokines such as IL-10 and via cell contact mechanisms (e.g., CTLA-4).

• Dysregulation leads to loss of tolerance, inflammation, and allergic symptoms.

• Risk Factors:

• Genetic predisposition: HLA alleles (e.g., HLA-B58:01* for drug reactions) significantly increase risk of severe T cell-mediated hypersensitivity.
• Environmental factors: cleaner environments, smaller family size (hygiene hypothesis) may increase allergic disease prevalence by limiting infection-driven TH1 polarization.
• Exposure to allergens and drugs known to cause T cell activation (e.g., nevirapine, allopurinol).

• Barrier dysfunction (skin, mucosal) promotes allergen sensitization.

• Protective Factors:

• Adequate Treg function maintaining immune tolerance.
• Early microbial exposures shaping a balanced immune response.
• Certain dendritic cell subsets fostering Treg induction via TGF-β and retinoic acid.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
• Delayed onset rash (e.g., maculopapular eruption), contact dermatitis.
• Urticaria and anaphylaxis are IgE-mediated but T cells contribute to chronic allergic inflammation.
• Symptoms of food allergy: pruritus, swelling, vomiting, anaphylaxis.

• Respiratory allergic symptoms: rhinitis, wheezing, asthma exacerbation.

• Early Signs:

• Mild skin erythema and itching (e.g., eczema flares).

• Initial mucosal irritation.

• Advanced Signs:

• Severe skin reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) linked to T cell–mediated cytotoxicity.
• Chronic inflammation with tissue remodeling (e.g., chronic asthma).

• Systemic symptoms in drug reaction with eosinophilia and systemic symptoms (DRESS).

• Atypical Presentations:

• Non-cutaneous manifestations such as hepatic or renal involvement in drug hypersensitivity.
• Gastrointestinal allergy symptoms without skin signs.

Physical Examination

• Inspection:
• Erythematous, widespread rash or localized dermatitis.
• Signs of atopic dermatitis: lichenification, excoriations.

• Mucosal ulcers in severe drug reactions.

• Palpation:

• Tenderness over affected areas, possible induration or swelling.

• Lymphadenopathy in systemic hypersensitivity reactions.

• Special Tests:

• Skin patch testing for delayed hypersensitivity.
• Skin prick tests more for IgE-mediated allergies but relevant in differential.

Diagnostic Approach

History Taking

• Key Questions:
• Recent drug exposures or new medications.
• Timing and progression of rash or symptoms.
• Past history of allergies or atopy.
• Family history of allergic diseases.

• Environmental exposures to allergens.

• Red Flags:

• Rapid progression to blistering or mucosal involvement (suggesting SJS/TEN).
• Systemic symptoms: fever, malaise, organ dysfunction.
• Respiratory distress or anaphylaxis signs.

Laboratory Tests

• First-Line:
• Complete blood count (CBC) looking for eosinophilia.
• Serum IgE and allergen-specific IgE testing.

• Liver and renal function tests in suspected systemic drug reactions.

• Confirmatory:

• Lymphocyte transformation tests (for drug hypersensitivity, though limited).
• HLA genotyping for risk alleles (e.g., HLA-B58:01*).

• Skin biopsy with histopathology for definitive diagnosis in severe cutaneous reactions.

• Monitoring:

• Regular CBC and organ function tests during systemic reactions.
• Clinical reassessment of allergic symptoms and treatment response.

Imaging

• Recommended:

• Generally not required for cutaneous or allergic presentations unless systemic involvement suspected (e.g., chest X-ray for asthma exacerbation).

• Advanced:

• CT or MRI if organ involvement suspected (e.g., liver or lung in drug hypersensitivity).

Management

Acute Management

• Immediate:
• Discontinue suspected causative drug/allergen immediately.
• Support airway and hemodynamics in anaphylaxis or severe reactions.

• Administer corticosteroids and antihistamines for immune modulation and symptom control.

• Stabilization:

• Intravenous fluids, oxygen supplementation if needed.

• Manage systemic complications (e.g., electrolyte balance, renal support).

• Emergency:

• Epinephrine for anaphylaxis.
• Hospitalization/ICU care for SJS/TEN or DRESS syndrome.

Chronic Management

• Pharmacological:
• Corticosteroids (topical, systemic) to control inflammation.
• Immunomodulators (e.g., cyclosporine, mycophenolate) in refractory cases.
• Biological therapies targeting cytokines (e.g., anti-IL-4/IL-13 for atopic dermatitis).

• Allergen immunotherapy considered in select allergic diseases.

• Non-pharmacological:

• Avoidance of known allergens and irritants.
• Skin barrier care with emollients in atopic dermatitis.

• Environmental controls to reduce allergen exposure.

• Monitoring:

• Regular follow-up for symptom control and adverse effects of therapy.
• Repeat testing to reassess sensitization status if relevant.

Treatment Algorithms

Line of Treatment	Description
First-Line	Immediate cessation of antigen/drug; corticosteroids and supportive care.
Second-Line	Immunosuppressive agents for severe/chronic disease; biologics in allergy.
Refractory	Consideration of advanced immunomodulation, plasmapheresis, or clinical trials for novel therapies (e.g., Treg enhancement).

Complications

• Common:
• Chronic dermatitis and skin scarring.

• Recurrent allergic exacerbations.

• Serious:

• SJS/TEN with high morbidity and mortality.
• Anaphylaxis with fatal risk.

• Multi-organ involvement in DRESS syndrome.

• Long-term:

• Chronic asthma or airway remodeling.
• Psychological impact and reduced quality of life from chronic allergic diseases.

Prognosis

• Factors:
• Severity and type of reaction.
• Promptness of causative agent withdrawal and treatment.

• Genetic predisposition and comorbidities.

• Survival:

• Generally good with mild reactions; high mortality in severe cutaneous adverse reactions (SJS/TEN ~10-30%).

• Anaphylaxis fatality is rare with prompt treatment.

• Quality of Life:

• May be impaired by chronic allergy symptoms and potential treatment adverse effects.

Prevention

• Primary:
• Avoidance of known allergens and high-risk drugs.
• Genetic screening for HLA alleles (e.g., HLA-B58:01* before allopurinol).

• Maintain healthy barrier function and microbial exposures in early life.

• Secondary:

• Early detection of symptoms and prompt treatment.

• Monitoring at-risk patients closely for adverse reactions.

• Tertiary:

• Prevention of complications via sustained therapy adherence and environmental control.

Special Populations

• Pediatric:
• Higher prevalence of food allergy (up to 8%).

• Consider developmental immune differences and need for age-appropriate dosing.

• Geriatric:

• Polypharmacy increases risk of drug hypersensitivity.

• Comorbidities impact treatment tolerance.

• Pregnancy:

• Some immunological tolerance changes occur; careful drug selection is required.

• Comorbidities:

• Asthma, eczema, and other atopic diseases commonly coexist.
• Autoimmune diseases may alter T cell responses and complicate management.

Clinical Pearls

• Diagnostic:
• Always consider recent drug exposures in delayed rash.

• HLA testing can predict severe drug hypersensitivity in certain ethnicities.

• Treatment:

• Early cessation of offending agent drastically improves outcome.

• Role of regulatory T cells offers therapeutic targets for immune modulation.

• Pitfalls:

• Misdiagnosis delaying drug withdrawal can worsen prognosis.
• Overreliance on IgE testing alone misses T cell–mediated allergies.

Recent Updates

• Guidelines:
• Increased recommendations for HLA screening before initiating high-risk drugs in certain populations.

• Updated algorithms for management of severe cutaneous adverse reactions.

• Evidence:

• Expanding knowledge on Treg subsets (Tr1 cells) and their role in inducing tolerance.

• Trials of biologics targeting T cell cytokines (IL-4, IL-13) show efficacy in allergic diseases.

• Controversies:

• Optimal strategies to induce immune tolerance in food allergy are under active research.
• Balancing immune suppression vs. infection risk remains challenging in severe cases.

Key References

• Guidelines:

• Clinical guidelines on drug hypersensitivity and allergy management from professional societies (e.g., AAAAI, EAACI).

• Studies:

• Association studies linking HLA alleles with severe T cell–mediated reactions.

• Immunological research delineating T cell subsets in allergy.

• Reviews:

• T Cell–Mediated Hypersensitivity Reactions to Drugs (PMC, 2014).
• Regulatory T cells in Allergic Diseases (PMC, 2016).
• The role of regulatory T cells in the acquisition of tolerance to food allergens (Allergologia, 2018).

---

This clinical reference synthesizes current evidence on T cell mediated allergic and hypersensitivity reactions with practical guidance for diagnosis, management, and prevention. Patient-specific factors and clinical judgment remain paramount.